- Home
- POLA vs PRPO Comparison
POLA vs PRPO Comparison
Compare POLA & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- POLA
- PRPO
- Stock Information
- Founded
- POLA 1979
- PRPO N/A
- Country
- POLA United States
- PRPO United States
- Employees
- POLA N/A
- PRPO 57
- Industry
- POLA Industrial Machinery/Components
- PRPO Biotechnology: Laboratory Analytical Instruments
- Sector
- POLA Miscellaneous
- PRPO Industrials
- Exchange
- POLA Nasdaq
- PRPO Nasdaq
- Market Cap
- POLA N/A
- PRPO 9.5M
- IPO Year
- POLA 2016
- PRPO N/A
- Fundamental
- Price
- POLA $0.45
- PRPO $6.59
- Analyst Decision
- POLA
- PRPO
- Analyst Count
- POLA 0
- PRPO 0
- Target Price
- POLA N/A
- PRPO N/A
- AVG Volume (30 Days)
- POLA 454.1K
- PRPO 7.9K
- Earning Date
- POLA 11-12-2024
- PRPO 11-11-2024
- Dividend Yield
- POLA N/A
- PRPO N/A
- EPS Growth
- POLA N/A
- PRPO N/A
- EPS
- POLA N/A
- PRPO N/A
- Revenue
- POLA $11,950,000.00
- PRPO $16,719,999.00
- Revenue This Year
- POLA $6.72
- PRPO $75.18
- Revenue Next Year
- POLA N/A
- PRPO N/A
- P/E Ratio
- POLA N/A
- PRPO N/A
- Revenue Growth
- POLA N/A
- PRPO 52.61
- 52 Week Low
- POLA $0.32
- PRPO $4.31
- 52 Week High
- POLA $0.98
- PRPO $8.99
- Technical
- Relative Strength Index (RSI)
- POLA 49.24
- PRPO 52.82
- Support Level
- POLA $0.44
- PRPO $6.42
- Resistance Level
- POLA $0.54
- PRPO $6.99
- Average True Range (ATR)
- POLA 0.07
- PRPO 0.33
- MACD
- POLA -0.01
- PRPO -0.04
- Stochastic Oscillator
- POLA 20.00
- PRPO 69.91
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.